Immunogenic cell death (ICD, also known as immunogenic apoptosis) of malignant cells is
confirmed to activate the host immune system to prevent, control, and eliminate tumors …

Cancer immunotherapy has tremendous promise, but it has yet to be clinically applied in a
wider variety of tumor situations. Many therapeutic combinations are envisaged to improve …

The therapeutic outcomes of oral nanomedicines against colon cancer are heavily
compromised by their lack of specific penetration into the internal tumor, favorable anti …

The reprogramming of tumor‐associated macrophages (TAMs) has emerged as an efficient
strategy for immunotherapy. However, most of the approaches did not allow the in situ …

Despite explosive growth in the development of nano-drug delivery systems (NDDS)
targeting tumors in the last few decades, clinical translation rates are low owing to the lack of …

Nanozymes, possessing enzyme-like characteristics, have emerged as valuable
nanomaterials in biomedical applications owing to their advantages over natural enzymes …

The tumor microenvironment (TME) plays an important role in various stages of tumor
generation, metastasis, and evasion of immune monitoring and treatment. TME targeted …

Primary tumors secrete a variety of factors to turn distant microenvironments into favorable
and fertile 'soil'for subsequent metastases. Among these 'seeding'factors that initiate pre …

Abstract Interleukin 2 (IL2) is the first approved immunotherapeutic agent in cancer
treatment. However, high‐dose IL2 administrated through intratumoral injection still spreads …

The extracellular matrix (ECM) is a major driver of fibrotic diseases and forms a dense
fibrous barrier that impedes nanodrug delivery. Because hyperthermia causes destruction of …